PDF(Pubmed)
Abstract：
To assess the efficacy of maintenance chemotherapy in the management of unresectable locally advanced pancreatic head adenocarcinoma (PHA) cancer after neoadjuvant chemotherapy and concurrent chemoradiation therapy (CCRT). This study, a large-scale head-to-head propensity score matching (PSM) cohort study, employed real-world data. PSM was used to evaluate the impact of maintenance chemotherapy on overall survival and cancer-specific survival in patients with unresectable locally advanced PHA who underwent neoadjuvant chemotherapy and CCRT. A total of 148 patients with locally advanced pancreatic head adenocarcinoma were included in the study after PSM. These patients were equally divided into two groups, those receiving maintenance chemotherapy and those who did not. Confounding factors were balanced between the groups. The adjusted hazard ratios for all-cause mortality and cancer-specific mortality were 0.56 (95% CI: 0.40-0.77; P = 0.0005) and 0.56 (95% CI: 0.40-0.78; P = 0.0007), respectively, in patients receiving maintenance chemotherapy compared to those who did not. Our large-scale, real-world study demonstrates that maintenance chemotherapy may enhance survival outcomes for patients with unresectable locally advanced pancreatic head adenocarcinoma who underwent neoadjuvant chemotherapy and concurrent chemoradiation therapy.
摘要：
评估新辅助化疗和同步放化疗（CCRT）后无法切除的局部晚期胰头腺癌（PHA）的维持化疗疗效。这项研究,大规模头对头倾向评分匹配（PSM）队列研究，使用真实世界的数据。PSM用于评估接受新辅助化疗和CCRT的不可切除的局部晚期PHA患者的总体生存率和癌症特异性生存率的影响。共有148例局部晚期胰头腺癌患者在PSM后被纳入研究。这些患者平均分为两组，那些接受维持化疗的人和那些没有接受维持化疗的人。混杂因素在组间平衡。全因死亡率和癌症特异性死亡率的校正风险比分别为0.56(95%CI:0.40-0.77;P=0.0005)和0.56(95%CI:0.40-0.78;P=0.0007)。分别,与未接受维持化疗的患者相比。我们的大规模，真实世界研究表明,对于接受新辅助化疗和同步放化疗治疗的不可切除的局部晚期胰头腺癌患者,维持化疗可提高生存结局.
